A new hybrid model for medical technology innovation.
Hybridge Medical serves as a bridge from invention to commercialization for innovative, value-based medical technologies that are aligned with the strategic interests of potential acquirers.
We develop new products that deliver improved outcomes to patients and providers, and healthy returns to inventors and investors. Our projects benefit from a hybrid “venture development” approach - utilizing the strengths of both VC and incubator models.
What We DO
Delivering impact and value for the 4 P’s, and a superior return to investors.
We develop medical technologies that create value-based innovation:
Better outcomes for Patients
Reduced expenses for Providers
Cost effectiveness for Payors
Competitive advantage for strategic Partners
At Hybridge, our mission is to serve as a bridge over the “valley of death” by enabling promising new technologies to come to market.
how we do it
Milestone driven development, right-sized scaling, with the end game in mind
We connect the dots from invention to expert development to strategic partnership or acquisition. Hybridge manages early stage innovation through multiple proof points to an appropriate end game for the technology in a top down or bottoms up approach. We access product ideas from sources of innovation where real-world, real-time product development occurs—at the front lines of clinical problem solving.
This venture development model takes advantage of a streamlined approach that generates clearly defined milestones that matter to project stakeholders.
Who We ARE
Proven leaders, passionate about early stage value creation
Our team possesses decades of expertise in building and leading medtech companies through all stages, as well as broad functional expertise, including:
Technology scouting and innovation sourcing
Business development and strategic partnering
Clinical research and studies
Lean, accelerated development
Innovation and milestone-driven product development
Quality management, operations and manufacturing
Regulatory approvals and compliance, HIPAA compliance
Market assessment, entry and penetration
Sales, partnering, development of distribution channels
Successful exits via acquisition and IPO
Why we do it
What we've seen in the market today
It is no secret that funding for early-stage medical device start-up companies is scarce, and the overall ecosystem and environment for medtech innovation is challenging. There is clear evidence in the market today that:
Most inventions, even patented inventions, never move from paper to reality.
Single product medical inventions are too small for professional venture capital investors to pay attention to and the capital requirements too large to bootstrap or rely on friends and family money to get to a value inflection point.
Early-stage angel investors are often so diluted upon exit the bar is much higher the second time around, if they even have the fortitude to do it again.
Medical technology executives who have not lived the medical start-up life lack the necessary knowledge to navigate the inevitable hurdles (predictable and unforeseen) and rollercoaster experiences, and there is a paucity of seasoned executives who are eager to work on early stage projects that often lack funding, definition, and direction.
Many projects are developed that do not meet a sufficient market or clinical need, or that lack a strategic partner’s interest, and often projects don’t have a sufficient end game in mind and languish.
Many large medical strategic players seek a dynamic channel for innovation in addition to their internal “invented here” R&D efforts or external, large-scale M&A efforts. They are looking for a process that:
leverages and increases the impact of their current R&D funds;
allows projects to proceed in alignment with their specific goals and interests;
adds to the future product funnel and has economics that fit their financial goals and appetite.
Hybridge Medical was created to address these issues. For more information or to explore this further, please contact us.
